Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: HIV Med. 2020 Nov 3;22(2):113–121. doi: 10.1111/hiv.12982

Table 4.

Performance of the D:A:D risk score

CHU Sourô Sanou CePReF CHUSO CIRBA Total

Discrimination
C-statistics 0.81 (0.78–0.84) 0.81 (0.78–0.84) 0.79 (0.73–0.86) 0.81 (0.77–0.85) 0.81 (0.79–0.83)
≥ 0 ≥ 5 ≥ 0 ≥ 5 ≥ 0 ≥ 5 ≥ 0 ≥ 5 ≥ 0 ≥ 5
 Sensitivity 81.5 61.4 74.4 57.3 90.7 76.7 80.2 61.1 79.4 60.9
 Specificity 64.4 83.6 73.5 89.1 44.3 71.3 66.3 85.1 66.5 84.9
 Calibration
Calibration (O/E)
 Low (score < 0) 2.28 (1.69–3.08) 2.52 (1.95–3.26) 1.50 (0.56–3.99) 2.45 (1.73–3.49) 2.38 (2.01–2.82)
 Medium (score 0–4) 0.76 (0.50–1.15) 0.72 (0.48–1.08) 0.58 (0.16–2.06) 0.87 (0.53–1.43) 0.74 (0.58–0.94)
 High (score ≥ 5) 0.43 (0.31–0.61) 0.49 (0.36–0.67) 0.40 (0.14–1.12) 0.45 (0.30–0.67) 0.43 (0.35–0.52)
 Total 1.23 (1.08–1.39) 1.51 (1.33–1.72) 0.66 (0.49–0.89) 1.37 (1.18–1.61) 1.27 (1.18–1.37)

CHU Sourô Sanou, University Teaching Hospital Sourô Sanou in Bobo Dioulasso, Burkina Faso; CePReF, the Centre de Prise en Charge, de Recherche et de Formation; CIRBA, Centre Intégré de Recherches Biocliniques d’Abidjan, Abidjan, Côte d’Ivoire; CHUSO, University Teaching Hospital Sylvanus Olympio, Lomé, Togo; O/E, number of observed/expected events according to the D:A:D model.